NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 3, 2023, to provide a corporate update and discuss details of the Company’s financial results for the quarter ended June 30, 2023.
To attend the live conference call by phone please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call.
The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
212-213-0006
LOS ANGELES, Jan. 11, 2025 /PRNewswire/ -- Demonstrating a commitment to both innovation and compassion,…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced…
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American:…
Craig Swandal, experienced medical device manufacturing executive, joins leadership teamALACHUA, Fla. and TAMPA, Fla., Jan.…
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…